Comparison of efficacy and safety of salvage-line nivolumab monotherapy between 240 and 480 mg for advanced esophageal squamous cell carcinoma.

被引：0
|
作者：
Murashima, Yuko
Yamamoto, Shun
Hirose, Toshiharu
Kadono, Toru
Ikeda, Go
Ohara, Akihiro
Itoyama, Mai
Yokoyama, Kazuki
Honma, Yoshitaka
Ishiyama, Koshiro
Oguma, Junya
Daiko, Hiroyuki
Kato, Ken
机构：
[1] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Esophageal Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
收藏
页码：317 / 317
页数：1
相关论文
共 50 条
  • [21] Correlation of combined positive score of PD-L1 expression and clinical efficacy for advanced esophageal squamous cell carcinoma treated with nivolumab monotherapy
    Mikuni, Hayato
    Yamamoto, Shun
    Sawada, Ryoichi
    Honma, Yoshitaka
    Sekine, Shigeki
    Oguma, Junya
    Saruta, Masayuki
    Daiko, Hiroyuki
    Kato, Ken
    Ishiyama, Koshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [22] Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma
    Rogers, Jane E.
    Yamashita, Kohei
    Sewastjanow-Silva, Matheus
    Rosa Vicentini, Ernesto
    Waters, Rebecca
    Ajani, Jaffer A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 565 - 571
  • [23] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [24] The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma
    Xu, Weili
    Jiang, Youhua
    Wang, Changchun
    Wu, Jie
    Li, Jianqiang
    Hu, Yuqian
    Lu, Weishan
    Shen, Dijian
    Wang, Yinjie
    Chen, Qixun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [25] Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
    Liu, Guohui
    Wang, Yanbo
    Wang, Chunbo
    He, Yunlong
    Mingyan, E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (12) : 1423 - 1430
  • [26] Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma
    Habu, Takumi
    Bando, Hideaki
    Kumanishi, Ryosuke
    Ogata, Takatsugu
    Fujisawa, Takeshi
    Kumagai, Shogo
    Fujiwara, Hisashi
    Mishima, Saori
    Kotani, Daisuke
    Nakamura, Masaki
    Hojo, Hidehiro
    Yoda, Yusuke
    Koyama, Shohei
    Nishikawa, Hiroyoshi
    Yano, Tomonori
    Fujita, Takeo
    Kadowaki, Shigenori
    Muro, Kei
    Kinoshita, Takahiro
    Kojima, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
    Wu, Zhigang
    Zheng, Qiang
    Chen, Haiquan
    Xiang, Jiaqing
    Hu, Hong
    Li, Hang
    Pan, Yunjian
    Peng, Yizhou
    Yao, Xingxin
    Liu, Pengcheng
    Sun, Yihua
    Li, Bin
    Zhang, Yawei
    JOURNAL OF THORACIC DISEASE, 2021, 13 (06) : 3518 - 3528
  • [28] Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review
    Xu, Jianming
    Bai, Yuxian
    Li, Enxiao
    Xu, Nong
    Shi, Danfeng
    Qian, Jing
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 981 - 998
  • [29] Nimotuzumab combined with chemotherapy plus immunotherapy as first-line treatment for advanced esophageal squamous cell carcinoma.
    Han, Quanli
    Wang, Qi
    Cui, Zhi
    Deng, Muhong
    Ma, Yue
    Pang, Fang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 344 - 344
  • [30] Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.
    Cong, Xiaofeng
    Xu, Zijun
    Liu, Ziling
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 205 - 205
12345